Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug

March 10, 2025 World Leave a comment 0 Views

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.

Check Also

Liver Cancer to Double Globally, Most Cases Preventable: Study

Rising Threat of Liver Cancer Liver cancer is expected to become a major global health …

Leave a Reply

Your email address will not be published. Required fields are marked *